Eisai joins the ADC golden rush
Pharmaceutical Technology
MAY 12, 2023
The agent is a human epidermal growth factor receptor 2 (HER2)-targeting ADC that utilises Eisai’s chemotherapy Halaven (eribulin) as its payload. GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). targeting ADC.
64 
Let's personalize your content